Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC

Inclusion Criteria: * Participants must be at least 18 years of age with a histologic diagnosis of adenocarcinoma of the prostate * Participants must have undergone radical prostatectomy * Participants must have completed local therapy by surgery, and any adjuvant/salvage radiation therapy (if required), at least 3 months prior to entry, with removal or ablation of all visible disease, including seminal vesical and/or local lymph node involvement. * Participants must have biochemically recurrent disease defined by the following: * PSA doubling time, calculated from most recent 4 serum PSA values (collected up to one year prior to enrollment, at least 2 weeks apart, and all from the same clinical laboratory), must be a positive number (i.e. evidence of PSA rise over time). * Participants must have oligometastatic disease, defined as: * \< 3 lesions consistent with metastases as detected by CT of the abdomen/pelvis and bone scintigraphy (bone scan) * Lesions consistent with metastatic prostate cancer as detected by PSMA PET/CT * Participants with a prior history of a second malignancy are eligible provided they have been treated with curative intent and have been free of disease greater than three years. There will be no exclusion for patients with a history of basal cell carcinoma, squamous cell skin cancer, superficial bladder cancer, or other in situ carcinoma that has been adequately treated. * Participants who are sexually active must use a reliable form of contra…